Results 181 to 190 of about 13,254 (218)

Imipenem‐Cilastatin‐Relebactam: A Novel β‐Lactam–β‐Lactamase Inhibitor Combination for the Treatment of Multidrug‐Resistant Gram‐Negative Infections

Pharmacotherapy, 2020
Imipenem‐cilastatin‐relebactam (IMI‐REL) is a novel β‐lactam–β‐lactamase inhibitor combination recently approved for the treatment of complicated urinary tract infections (cUTIs) and complicated intraabdominal infections (cIAIs).
Jordan R. Smith, J. Rybak, K. Claeys
semanticscholar   +1 more source

Untargeted metabolomics analysis of serum and urine unveils the protective effect of cilastatin on altered metabolic pathways during cisplatin-induced acute kidney injury.

Biochemical Pharmacology
Acute kidney injury (AKI) is one of the most serious complications of cisplatin anticancer therapies. Cilastatin is a highly promising nephroprotective agent to eventually enter clinical use, but its biochemical mechanism is still not fully understood ...
E. Moreno-Gordaliza, M. González-Nicolás, Alberto Lázaro, C. Barbas, M. Gómez-Gómez, Á. López-Gonzálvez   +5 more
semanticscholar   +1 more source

Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.

Lancet. Infectious Diseases (Print), 2018
BACKGROUND Carbapenem-resistant Gram-negative bacteria represent the highest priority for addressing global antibiotic resistance. Cefiderocol (S-649266), a new siderophore cephalosporin, has broad activity against Enterobacteriaceae and non-fermenting ...
S. Portsmouth, D. V. van Veenhuyzen, R. Echols, M. Machida, J. Ferreira, M. Ariyasu, P. Tenke, T. Nagata   +7 more
semanticscholar   +1 more source

Eco-Friendly Synchronous Spectrofluorimetric Determination of Imipenem, Cilastatin, and Relebactam; Application to Market Formulations and Biological Fluids; Greenness Assessment

Journal of Fluorescence
The proposed study introduces a rapid, sensitive, and simple synchronous spectrofluorimetric technique for simultaneous quantification of relebactam, cilastatin, and imipenem in marketed pharmaceutical forms and biological fluids.
Hesham Salem, Mahmoud A. Abdelmajed, Nadeen Emad, Belal M. Abdelghany, Anas Mahmoud, Amir Ata, Mahmoud Abdelgaleel   +6 more
semanticscholar   +1 more source

The safety and efficacy of relebactam/imipenem/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: A multicenter, open-label, noncomparative phase 3 study.

Journal of Infection and Chemotherapy, 2020
INTRODUCTION Relebactam, a novel class A/C β-lactamase inhibitor developed as a fixed-dose combination with imipenem/cilastatin, restores imipenem activity against imipenem-nonsusceptible gram-negative pathogens. METHODS This phase 3, multicenter, open-
S. Kohno, H. Bando, F. Yoneyama, H. Kikukawa, K. Kawahara, Masayoshi Shirakawa, Norihiro Aoyama, M. Brown, Amanda Paschke, A. Takase   +9 more
semanticscholar   +1 more source

Imipenem + Cilastatin

Reactions Weekly, 2016
  +5 more sources

GAUCHO - Trial Genicular Artery Embolization Using Imipenem/Cilastatin vs. Microsphere for Knee Osteoarthritis: A Randomized Controlled Trial

Cardiovascular and Interventional Radiology, 2022
M. Corrêa, J. M. Motta-Leal-Filho, Ricardo Lugokeski, M. Mezzomo, L. Leite   +4 more
semanticscholar   +1 more source

Imipenem/cilastatin

Reactions Weekly, 1993
  +5 more sources

Imipenem/cilastatin

Reactions Weekly, 2023
openaire   +2 more sources

Intra-arterial infusion of imipenem cilastatin sodium through a needle inserted into radial artery as a new treatment for refractory trapeziometacarpal osteoarthritis.

Journal of Vascular and Interventional Radiology, 2021
Shohei Inui, Shu Yoshizawa, T. Shintaku, T. Kaneko, H. Ikegami, Y. Okuno   +5 more
semanticscholar   +1 more source